Obstetrics & Gynaecology · FOGSI

Postpartum haemorrhage

FOGSI

Source:FOGSI FOCUS Update — Factor VIIa in Severe PPH Management (2024)WHO Recommendations on the Management of Postpartum Haemorrhage (2024)FIGO PPH guideline (2024)

Verified Apr 2026

Ask House about this guideline

Red Flags

Severe primary PPH (>1000 mL or signs of haemodynamic compromise) — major obstetric haemorrhage protocol; cross-match 4 units; multidisciplinary team^[1]
Suspected uterine inversion — emergency replacement under anaesthesia; stop oxytocics; tocolysis (terbutaline, GTN) if rigid^[1]
Persistent bleeding despite uterotonics and tranexamic acid — proceed to surgical haemostasis (intra-uterine balloon, B-Lynch, internal iliac ligation, hysterectomy)^[1]
Disseminated intravascular coagulation with persistent bleeding — replace clotting factors (FFP, cryoprecipitate, platelets); consider rFVIIa as last-resort adjunct^[1]

First-line treatment

Interventions

Active management of third stage of labour (prevention)^[1]
Oxytocin 10 IU IM (or 5 IU slow IV) within 1 minute of delivery; controlled cord traction with delivery of placenta; uterine massage after placenta. Reduces PPH by 50%
Stepwise PPH protocol^[1]
Call for help → A-B-C with O2 + 2 large-bore IV → bimanual uterine compression → uterotonics → tranexamic acid → uterine tamponade balloon → surgical haemostasis (B-Lynch, vessel ligation, hysterectomy as ultimate measure)
Resuscitation with balanced ratios^[1]
Massive haemorrhage protocol with packed cells:FFP:platelets ~1:1:1; cryoprecipitate when fibrinogen <2 g/L; warm fluids; correct hypothermia, acidosis, hypocalcaemia (lethal triad)
Uterine balloon tamponade^[1]
Bakri or condom-catheter tamponade for atonic PPH refractory to uterotonics; bridge to surgical management or transfer; effective in 80–90% when first-line drug therapy fails

First-line drug therapy

Drug	Class	Adult	Paediatric	Notes
Oxytocin^[1]	Synthetic oxytocin	10 IU IM or 5 IU slow IV (over 1 min) followed by 40 IU in 500 mL crystalloid IV at 125 mL/h	—	First-line uterotonic for prevention and treatment of PPH; thermolabile — store cold; no hypertension contraindication
Tranexamic acid^[1]	Antifibrinolytic	1 g IV over 10 min within 3 hours of PPH onset; repeat 1 g IV after 30 min if bleeding continues	—	WOMAN trial showed mortality reduction in PPH; second-line after oxytocin; can be combined with uterotonics
Carboprost (15-methyl PGF2α)^[1]	Prostaglandin F2α analogue	250 µg IM (or intramyometrial); repeat every 15 min, max 2 mg total	—	Refractory atonic PPH; contraindicated in asthma, hypertension, severe cardiac disease; bronchospasm and diarrhoea common
Misoprostol^[1]	Synthetic prostaglandin E1	800 µg sublingual or rectal	—	Adjunct to or substitute for oxytocin where unavailable; pyrexia, shivering common; useful in primary care or low-resource settings
Ergometrine (methylergometrine)^[1]	Ergot alkaloid	0.2 mg IM or slow IV, repeat every 2–4 h, max 5 doses	—	Second-line uterotonic; CONTRAINDICATED in hypertension, pre-eclampsia, severe cardiac disease; hypertensive crisis risk
Recombinant factor VIIa (rFVIIa) — last-resort adjunct^[1]	Recombinant coagulation factor VIIa	60–90 µg/kg IV bolus; may repeat after 15–30 min if needed	—	Adjunct in life-threatening PPH refractory to standard surgical and pharmacological measures, with corrected acidosis, hypothermia, and platelets/fibrinogen replenished; thrombotic risk; specialist decision

Oxytocin^[1]

Synthetic oxytocin

Adult: 10 IU IM or 5 IU slow IV (over 1 min) followed by 40 IU in 500 mL crystalloid IV at 125 mL/h
Paediatric: —

First-line uterotonic for prevention and treatment of PPH; thermolabile — store cold; no hypertension contraindication

Tranexamic acid^[1]

Antifibrinolytic

Adult: 1 g IV over 10 min within 3 hours of PPH onset; repeat 1 g IV after 30 min if bleeding continues
Paediatric: —

WOMAN trial showed mortality reduction in PPH; second-line after oxytocin; can be combined with uterotonics

Carboprost (15-methyl PGF2α)^[1]

Prostaglandin F2α analogue

Adult: 250 µg IM (or intramyometrial); repeat every 15 min, max 2 mg total
Paediatric: —

Refractory atonic PPH; contraindicated in asthma, hypertension, severe cardiac disease; bronchospasm and diarrhoea common

Misoprostol^[1]

Synthetic prostaglandin E1

Adult: 800 µg sublingual or rectal
Paediatric: —

Adjunct to or substitute for oxytocin where unavailable; pyrexia, shivering common; useful in primary care or low-resource settings

Ergometrine (methylergometrine)^[1]

Ergot alkaloid

Adult: 0.2 mg IM or slow IV, repeat every 2–4 h, max 5 doses
Paediatric: —

Second-line uterotonic; CONTRAINDICATED in hypertension, pre-eclampsia, severe cardiac disease; hypertensive crisis risk

Recombinant factor VIIa (rFVIIa) — last-resort adjunct^[1]

Recombinant coagulation factor VIIa

Adult: 60–90 µg/kg IV bolus; may repeat after 15–30 min if needed
Paediatric: —

Adjunct in life-threatening PPH refractory to standard surgical and pharmacological measures, with corrected acidosis, hypothermia, and platelets/fibrinogen replenished; thrombotic risk; specialist decision

Safety-net

Continued vigilance for ≥24 hours postpartum — secondary PPH can occur up to 12 weeks; report heavy bleeding, foul-smelling discharge, or fever^[1]
Ensure iron repletion postpartum — IV iron preferred for severe blood loss anaemia to enable breastfeeding and rapid recovery^[1]
Counsel about future pregnancy planning — recurrence risk increases with prior PPH; planned delivery in well-equipped unit^[1]

Referral criteria

Active PPH refractory to uterotonics and tranexamic acidSenior obstetrician, anaesthetic team, blood bank; theatre^[1]
Need for surgical haemostasis (B-Lynch, internal iliac ligation, hysterectomy)Theatre with experienced operator; involve interventional radiology where available^[1]
Suspected coagulopathy (DIC, prior bleeding disorder)Haematology / massive transfusion protocol^[1]
Antenatal high-risk (prior PPH, accreta, multiple pregnancy, severe anaemia)Plan delivery in unit with blood bank, theatre, anaesthetic, and IR access^[1]

Clinical summary

Recognition, resuscitation, and stepwise pharmacological and surgical management of primary postpartum haemorrhage and the role of rFVIIa.

References

1.FOGSI FOCUS Update — Factor VIIa in Severe PPH Management (2024); WHO Recommendations on the Management of Postpartum Haemorrhage; FIGO PPH guideline (2024)

Drug

Class

Adult

Paediatric

Notes